As expected, the European Commission approves Pfizer’s (NYSE:PFE) Vyndaqel (tafamidis) for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM), the first drug approved in Europe for the indication.
About two months ago, the advisory group CHMP adopted a positive opinion backing approval.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.